Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis

Molecular and Cellular Biology

Volumn 32, Issue 17, 2012, Pages 3486-3499

  Rada, Patricia ^a   Rojo, Ana I ^a,b   Evrard Todeschi, Nathalie ^c   Innamorato, Nadia G ^a   Cotte, Axelle ^c   Jaworski, Tomasz ^d,g   Tobón Velasco, Julio C ^a   Devijver, Herman ^d   García Mayoral, María Flor ^e   Van Leuven, Fred ^d   Hayes, John D ^f   Bertho, Gildas ^c   Cuadrado, Antonio ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ARGININE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3BETA; MALONALDEHYDE; SERINE; TRANSCRIPTION FACTOR NRF2;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE PRODUCT; HUMAN; HUMAN CELL; HYDROPHOBICITY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; STATIC ELECTRICITY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

AMINO ACID SEQUENCE; ANIMALS; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CELLS, CULTURED; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NF-E2-RELATED FACTOR 2; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; SERINE;

MUS;

EID: 84866283856     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00180-12     Document Type: Article

References (56)

1. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. 1997. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16:3797-3804.
2. Bax A, Davis DG. 1985. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. J. Magn. Reson. 65:355-360.
3. Blanco FJ, Rivas G, Serrano L. 1994. A short linear peptide that folds into a native stable beta-hairpin in aqueous solution. Nat. Struct. Biol. 1:584-590.
4. Chan K, Lu R, Chang JC, Kan YW. 1996. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc. Natl. Acad. Sci. U. S. A. 93:13943-13948.
5. Coadou G, et al. 2003. NMR studies of the phosphorylation motif of the HIV-1 protein Vpu bound to the F-box protein beta-TrCP. Biochemistry 42:14741-14751.
6. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. 2004. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol. Cell. Biol. 24:8477-8486.
7. Dajani R, et al. 2003. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 22:494-501.
8. Feldman RM, Correll CC, Kaplan KB, Deshaies RJ. 1997. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91:221-230.
9. Frescas D, Pagano M. 2008. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 8:438-449.
10. Furukawa M, Xiong Y. 2005. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell. Biol. 25:162-171.
11. Galvan-Arzate S, et al. 2005. Delayed effects of thallium in the rat brain: regional changes in lipid peroxidation and behavioral markers, but moderate alterations in antioxidants, after a single administration. Food Chem. Toxicol. 43:1037-1045.
12. Garcia E, et al. 2008. Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine. Free Radic. Res. 42:892-902.
13. Hayes JD, Mcmahon M. 2009. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 34: 176-188.
14. Hwang TL, Shaka AJ. 1995. Water suppression that works-excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J. Magn. Reson. 112:275-279.
15. Itoh K, et al. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236:313-322.
16. Itoh K, et al. 1999. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13:76-86.
17. Jain AN. 2003. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 46:499-511.
18. Jaworski T, et al. 2011. GSK-3alpha/beta kinases and amyloid production in vivo. Nature 480:E4-5, E6.
19. Jazwa A, et al. 2011. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid. Redox. Signal. 14:2347-2360.
20. Kanemori Y, Uto K, Sagata N. 2005. Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc. Natl. Acad. Sci. U. S. A. 102:6279-6284.
21. Katoh Y, et al. 2005. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch. Biochem. Biophys. 433:342-350.
22. Kobayashi A, et al. 2004. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 24:7130-7139.
23. Kockeritz L, Doble B, Patel S, Woodgett JR. 2006. Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr. Drug Targets 7:1377-1388.
24. Latres E, Chiaur DS, Pagano M. 1999. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18:849-854.
25. Linge JP, Habeck M, Rieping W, Nilges M. 2003. ARIA: automated NOE assignment and NMR structure calculation. Bioinformatics 19:315-316.
26. Lo SC, Li X, Henzl MT, Beamer LJ, Hannink M. 2006. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J. 25:3605-3617.
27. Martin D, et al. 2004. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J. Biol. Chem. 279:8919-8929.
28. Mcmahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. 2006. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "ethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 281:24756-24768.
29. Mcmahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. 2004. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redoxinsensitive Neh6 degron. J. Biol. Chem. 279:31556-31567.
30. Megy S, et al. 2005. STD and TRNOESY NMR studies on the conformation of the oncogenic protein beta-catenin containing the phosphorylated motif DpSGXXpS bound to the beta-TrCP protein. J. Biol. Chem. 280: 29107-29116.
31. Molina-Jijon E, et al. 2011. Curcumin prevents Cr(VI)-induced renal oxidant damage by a mitochondrial pathway. Free Radic. Biol. Med. 51: 1543-1557.
32. Pan Y, Bai CB, Joyner AL, Wang B. 2006. Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. Mol. Cell. Biol. 26:3365-3377.
33. Papkoff J, Aikawa M. 1998. WNT-1 and HGF regulate GSK3 beta activity and beta-catenin signaling in mammary epithelial cells. Biochem. Biophys. Res. Commun. 247:851-858.
34. Piotto M, Saudek V, Sklenar V. 1992. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J. Biomol. NMR 2:661-665.
35. Pons J, et al. 2007. Structural studies on 24P-IkappaBalpha peptide derived from a human IkappaB-alpha protein related to the inhibition of the activity of the transcription factor NF-kappaB. Biochemistry 46:2958-2972.
36. Pons J, et al. 2008. Transfer-NMR and docking studies identify the binding of the peptide derived from activating transcription factor 4 to protein ubiquitin ligase beta-TrCP. Competition STD-NMR with beta-catenin. Biochemistry 47:14-29.
37. Pons J, Tanchou V, Girault JP, Bertho G, Evrard-Todeschi N. 2011.NMR applications for identifying beta-TrCP protein-ligand interactions. Mini Rev. Med. Chem. 11:283-297.
38. Rada P, et al. 2011. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell. Biol. 31:1121-1133.
39. Rojo AI, et al. 2010. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58:588-598.
40. Rojo AI, et al. 2012. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: role of glycogen synthase kinase-3. Free Radic. Biol. Med. 52:473-487.
41. Rojo AI, et al. 2008. Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol. Cell. Neurosci. 39:125-132.
42. Rojo AI, Sagarra MR, Cuadrado A. 2008. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J. Neurochem. 105:192-202.
43. Rushmore TH, Kong AN. 2002. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metab. 3:481-490.
44. Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW. 1997. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91:209-219.
45. States DJ, Haberkorn RA, Ruben DJ. 1982. A two-dimensional nuclear Overhauser experiment with pure absorption phase in four quadrants. J. Magn. Reson. 48:286-292.
46. Taguchi K, Motohashi H, Yamamoto M. 2011. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16:123-140.
47. Tong KI, Kobayashi A, Katsuoka F, Yamamoto M. 2006. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol. Chem. 387:1311-1320.
48. Venugopal R, Jaiswal AK. 1996. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response elementmediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. U. S. A. 93:14960-14965.
49. Wang B, Li Y. 2006. Evidence for the direct involvement of βTrCP in Gli3 protein processing. Proc. Natl. Acad. Sci. U. S. A. 103:33-38.
50. Watanabe N, et al. 2004. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc. Natl. Acad. Sci. U. S. A. 101:4419-4424.
51. Willker W, Leibfritz D, Kerssebaum R, Bermel W. 1993. Gradient selection in inverse heteronuclear correlation spectroscopy. Magn. Reson. Chem. 31:287-292.
52. Wu G, et al. 2003. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol. Cell 11:1445-1456.
53. Wüthrich K. 1986. NMR of proteins and nucleic acids. John Wiley & Sons, New York, NY.
54. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. 2004. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 24:10941-10953.
55. Zhou BP, et al. 2004. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6:931-940.
56. Zhu Z, Kirschner M. 2002. Regulated proteolysis of Xom mediates dorsoventral pattern formation during early Xenopus development. Dev. Cell 3:557-568.